(Q34855129)

English

A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

phase II clinical trial

0 references

multicenter clinical trial

0 references

randomized experiment

1 reference

based on heuristic

inferred from title

object named as

Domenico Sergi

4

0 references

object named as

Enrico Vizza

8

0 references

Diana Giannarelli

object named as

Diana Giannarelli

12

0 references

1

object named as

Patrizia Vici

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Giuseppe Colucci

2

object named as

Giuseppe Colucci

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Gianfranco Filippelli

5

object named as

Gianfranco Filippelli

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

author name string

Francesco Giotta

3

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Pasquale Perri

6

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Claudio Botti

7

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Armando Carpino

9

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Laura Pizzuti

10

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Agnese Latorre

11

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Massimo Lopez

13

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Luigi Di Lauro

14

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

publication date

12 April 2011

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Journal of Experimental & Clinical Cancer Research

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

39

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

copyright license

Creative Commons Attribution 2.0 Generic

12 April 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

randomized experiment

0 references

Different anthracycline derivates for reducing cardiotoxicity in cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082232

8 July 2018

Different anthracycline derivates for reducing cardiotoxicity in cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082232

8 July 2018

Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082232

8 July 2018

First-line chemotherapy for HER-2 negative metastatic breast cancer patients who received anthracyclines as adjuvant treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082232

8 July 2018

Role of liposomal anthracyclines in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082232

8 July 2018

Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082232

8 July 2018

Sequential docetaxel followed by epirubicin-vinorelbine as first-line chemotherapy in advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082232

8 July 2018

Chemotherapy: what progress in the last 5 years?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082232

8 July 2018

Phase II study of pegylated liposomal doxorubicin plus vinorelbine in breast cancer with previous anthracycline exposure.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082232

8 July 2018

Antitumour antibiotic containing regimens for metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082232

8 July 2018

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082232

8 July 2018

Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. A phase I-II clinical investigation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082232

8 July 2018

First-line treatment with epirubicin and vinorelbine in metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082232

8 July 2018

Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082232

8 July 2018

Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082232

8 July 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082232

8 July 2018

The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082232

8 July 2018

Drugs ten years later: epirubicin.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082232

8 July 2018

Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082232

8 July 2018

Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082232

8 July 2018

Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group

1 reference

https://api.crossref.org/works/10.1186%2F1756-9966-30-39

21 January 2018

Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1186%2F1756-9966-30-39

21 January 2018

Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1186%2F1756-9966-30-39

21 January 2018

Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1186%2F1756-9966-30-39

21 January 2018

Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1186%2F1756-9966-30-39

21 January 2018

Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403).

1 reference

https://api.crossref.org/works/10.1186%2F1756-9966-30-39

21 January 2018

A phase II trial of vinorelbine and pegylated liposomal doxorubicin in patients with pretreated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1186%2F1756-9966-30-39

21 January 2018

Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1186%2F1756-9966-30-39

21 January 2018

Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women > or = 65 years of age.

1 reference

https://api.crossref.org/works/10.1186%2F1756-9966-30-39

21 January 2018

Sample size tables for exact single-stage phase II designs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082232

26 October 2018

Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082232

26 October 2018

Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082232

26 October 2018

A prospective, randomized Phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/21481280

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: A high-activity, dose-dense weekly regimen for advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21481280

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/21481280

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21481280

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: a prospective randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21481280

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vinorelbine and epirubicin in metastatic breast cancer. A dose finding study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21481280

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/21481280

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epirubicin/vinorelbine as first line therapy in metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21481280

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1756-9966-30-39

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34855129&oldid=2197063368"